In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Combinations Continue To Drive Immuno-Oncology Deal-Making

Executive Summary

The pursuit by the industry to find novel combinations that can address more patients and more tumor types has driven overall immuno-oncology deal activity by big pharma and mid pharma companies between 2012 and 2016.


Related Content

Immuno-Oncology Is Making Pharma Step Up Its Diagnostics Game
Immuno-oncology Drugs And The Trouble With Market Access
With A New CSO, Bristol-Myers Squibb Doubles Down On Immuno-Oncology
Big Pharma Licensing Growth Slows In 2016
BMS M&A Q&A: Is IO Player Now In Play? Lung Cancer Moves Seen As Key
Bristol Falls Further Behind Merck In NSCLC By Pulling Early Combo Filing
It’s Here: Merck’s Keytruda Cleared For First-Line Lung Cancer
Key Trends In Immuno-Oncology Dealmaking


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts